Company Participants
Ezgi Yagci – Vice President of Investor Relations
Timothy Herbert – Founder, Chairman, CEO & President
Matthew Osberg – Executive VP & CFO
Conference Call Participants
Lilia-Celine Lozada – JPMorgan Chase & Co, Research Division
Jonathan Block – Stifel, Nicolaus & Company, Incorporated, Research Division
Adam Maeder – Piper Sandler & Co., Research Division
Christopher Pasquale – Nephron Research LLC
Anthony Petrone – Mizuho Securities USA LLC, Research Division
Travis Steed – BofA Securities, Research Division
Larry Biegelsen – Wells Fargo Securities, LLC, Research Division
Richard Newitter – Truist Securities, Inc., Research Division
Michael Polark – Wolfe Research, LLC
Shagun Singh Chadha – RBC Capital Markets, Research Division
David Rescott – Robert W. Baird & Co. Incorporated, Research Division
Michael Sarcone – Jefferies LLC, Research Division
Brett Fishbin – KeyBanc Capital Markets Inc., Research Division
Daniel Markowitz – Evercore ISI Institutional Equities, Research Division
Michael Kratky – Leerink Partners LLC, Research Division
Presentation
Operator
Good afternoon. My name is [ Dilem ], and I’ll be your conference operator today. At this time, I’d like to welcome everyone to the Inspire Medical Systems First Quarter 2026 Conference Call. [Operator Instructions] I’ll now hand the conference over to your first speaker, Ezgi Yagci, the Vice President of Investor Relations at Inspire. You may begin the conference.
Ezgi Yagci
Vice President of Investor Relations
Thank you, [ Dilem ], and thank you all for participating in today’s call. Joining me are Tim Herbert, Chairman and Chief Executive Officer; and Matt Osberg, Chief Financial Officer. Earlier today, we released financial results for the 3 months ended March 31, 2026. A copy of the press release is available on our website. On this call, management will make forward-looking statements within the meaning of the federal securities laws. All forward-looking statements, including, without limitation, those relating to our operations, financial results and financial condition, investments in our business, full year 2026 financial and operational
